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Molecular targeted drugs have been extensively introduced to 
pharmacotherapy in the field of cancer, including hematologic malignancies 
(Table). Compared with other solid tumors, one of the unique characteristics 
of hematologic malignancies is the marked chemosensitivity of neoplastic 
cells to conventional chemotherapy. So, before the era of molecular targeted 
therapy, hematologic malignancies such as acute lymphocytic leukemia in 
childhood, Burkitt’s lymphoma / leukemia, and Hodgkin’s disease were 
curable with conventional combination chemotherapy, and other hematologic 
malignancies such as acute myeloid leukemia, acute lymphocytic leukemia of 
adulthood, and some subsets of lymphoma were also relatively curable with 
conventional chemotherapy. Thus, the benefits of the introduction of 
molecular targeted agents for hematologic malignancies are clinically 
thought to be mainly classifiable into 3 categories: (1) Increase the cure rate 
of already chemotherapeutically curable malignancies. (2) Cure 
chemotherapeutically resistant malignancies. (3) Achieve some therapeutic 
effect (but not yet cure ) against chemotherapeutically resistant 
malignancies.  
In category (1), the representative is rituximab, a chimeric murine / 
human anti-CD20 monoclonal antibody, for malignant lymphoma. 
Non-Hodgkin’s lymphoma is curable with combination chemotherapy of 
CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or a 
CHOP-like regimen. Much evidence has been reported that survival rates 
are significantly increased by the addition of rituximab to CHOP or a 
CHOP-like regimen in diffuse large B-cell lymphoma [1] and follicular 
lymphoma [2] patients. In category (2), there are drugs targeting abnormal 
molecules specific to neoplastic cells [3]. A series of bcr-abl tyrosine kinase 
inhibitors for chronic myeloid leukemia are commonly known [4]. Imatinib 
mesylate, a well-known first-generation drug, was initially reported as a 
molecular targeted drug synthesized pharmacogenomically that exhibited  
a marked antileukemic (antineoplastic) effect (approved in 2001 in the US). 
Other important issues regarding this kind of drug are its rapid synthesis 
and clinical application as second-and third-generation drugs for bcr-abl 
tyrosine kinase inhibitors (shown in parenthesis), which were synthesized to 
overcome imatinib resistance due to the emergence of mutant clones of 
bcr-abl. The second-generation drugs, dasatinib (in 2006) and nilotinib (in 
2007) are effective for most mutant clones except T315I [5]. The 
third-generation drug ponatinib (in 2012) is effective against mutants 
including T315I [5]. From now on, as a crucial matter, how to knock out CML 
stem cells should be extensively studied both basically and clinically. Also, 
several studies on how to stop tyrosine kinase inhibitors in the clinic are 
ongoing, which is important both clinically and economically. In category (3) 
are drugs for diseases including myelodysplastic syndrome ( MDS ) and 
multiple myeloma. Especially, MDS is a clonal hematopoietic stem cell 
disease for which no standard therapy exists. Recently, azacytidine, a 
cytidine analog which was synthesized in 1963, was focused on regarding its 
epigenetic effect as a demethylating agent by inhibiting DNA cytosine 
methylation and, as a result, increasing the expression of a suppressed gene. 
The drug is thought to be the first shown to be effective against 
myelodysplastic syndromes, significantly prolonging the survival of patients 
compared with a control [6]. 
In conclusion, currently, molecular targeted drugs synthesized 
pharmacogenomically may show marked effects such as cure against some of 
resistant cancers. Moreover, this kind of drug more effectively increases the 
survival rate and more rapidly improves the QOL compared with 
conventional anticancer agents, and could be safer if administered by 
professional hemato-oncologists to patients with hematologic malignancies.  
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